Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.

Xinhang Xia Wenhu Pi Yanli Lan Xiaomai Wu Dongqing Lv Yinnan Meng Haihua Yang Wei Wang

Published in: Analytical cellular pathology (Amsterdam) (2022)

Our data revealed that the treatment of combination of antitumor angiogenesis agent anlotinib with chemotherapy drug 5-FU may have synergistic cytotoxicity to SCLC in vitro and in vivo. This treatment modality reduced cell proliferation and migration via Src/AKT pathway. This new strategy may be a promising treatment for SCLC but needs to be confirmed in future clinical trials.

Keyphrases

signaling pathway
small cell lung cancer
clinical trial
single cell
randomized controlled trial
emergency department
squamous cell carcinoma
pi k akt
machine learning
stem cells
replacement therapy
vascular endothelial growth factor
drug delivery
endoplasmic reticulum stress
data analysis
rectal cancer